Scarica l'app Stockscreener
6.06
5.41%
-0.41
Outlook Therapeutics Inc Borsa (OTLK) Ultime notizie
Outlook Therapeutics® to Participate in the Virtual Investor Closing Bell Series - GlobeNewswire
Outlook Therapeutics® Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference Series - GlobeNewswire
Outlook Therapeutics® Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference Series - StockTitan
OTLKOutlook Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Outlook Therapeutics Inc (OTLK) Becoming More Attractive for Investors - Knox Daily
Private equity firms are Outlook Therapeutics, Inc.'s (NASDAQ:OTLK) biggest owners and were rewarded after market cap rose by US$30m last week - Simply Wall St
Outlook Therapeutics, Inc. (NASDAQ:OTLK) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Outlook Therapeutics Inc [OTLK] Shares Jump Approximately 62.65% Over the Year - Knox Daily
Outlook Therapeutics completes NORSE EIGHT enrollment - Investing.com
Outlook Therapeutics® Announces Completion of Enrollment in NORSE EIGHT Clinical Trial - GlobeNewswire
Outlook Therapeutics® Announces Completion of Enrollment in NORSE EIGHT Clinical Trial - StockTitan
Outlook Therapeutics (NASDAQ:OTLK) Price Target Lowered to $33.00 at Ascendiant Capital Markets - Defense World
Ascendiant Capital Markets Lowers Outlook Therapeutics (NASDAQ:OTLK) Price Target to $33.00 - MarketBeat
Outlook Therapeutics® to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire
Outlook Therapeutics® to Present at the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
OTLK’s latest rating updates from top analysts. - Knox Daily
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Outlook Therapeutic - GuruFocus.com
Outlook Therapeutics: Poised To Jump With Wet AMD Treatment If It Can Overcome FDA Hurdles - Seeking Alpha
Outlook Therapeutics Inc [OTLK] Investment Guide: What You Need to Know - Knox Daily
Outlook Therapeutics, Inc. (NASDAQ:OTLK) Forecasted to Earn FY2024 Earnings of ($3.90) Per Share - MarketBeat
Vanguard Group Inc. Has $4.08 Million Stock Holdings in Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World
Vanguard Group Inc. Sells 6,219,100 Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) - MarketBeat
Outlook Therapeutics, Inc. (NASDAQ:OTLK) Expected to Post FY2024 Earnings of ($3.90) Per Share - Defense World
Chardan Capital Reiterates “Buy” Rating for Outlook Therapeutics (NASDAQ:OTLK) - Defense World
Outlook Therapeutics (NASDAQ:OTLK) Rating Reiterated by HC Wainwright - Defense World
Outlook Therapeutics, Inc. (NASDAQ:OTLK) to Post FY2027 Earnings of $1.17 Per Share, HC Wainwright Forecasts - Defense World
Outlook Therapeutics (NASDAQ:OTLK) Stock Rating Reaffirmed by Chardan Capital - MarketBeat
Brokerages Set Outlook Therapeutics, Inc. (NASDAQ:OTLK) Price Target at $46.43 - MarketBeat
OTLK (Outlook Therapeutics) EV-to-Revenue : (As of Aug. 16, 2024) - GuruFocus.com
Outlook Therapeutics, Inc. to Post FY2027 Earnings of $1.17 Per Share, HC Wainwright Forecasts (NASDAQ:OTLK) - MarketBeat
Outlook Therapeutics, Inc. (NASDAQ:OTLK) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of O - GuruFocus.com
HC Wainwright Reiterates "Buy" Rating for Outlook Therapeutics (NASDAQ:OTLK) - MarketBeat
Outlook Therapeutics, Inc. (NASDAQ:OTLK) Q3 2024 Earnings Call Transcript - Insider Monkey
Outlook Therapeutics Inc (OTLK) Q3 2024 Earnings Call Transcript - GuruFocus.com
Q3 2024 Outlook Therapeutics Inc Earnings Call Transcript - GuruFocus.com
Investing in Outlook Therapeutics Inc (OTLK): What You Must Know - Knox Daily
Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2024 and Provides Corporate Update - GlobeNewswire
Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2024 and Provides Corporate Update - wallstreet:online
Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2024 and Provides Corporate Update - StockTitan
Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2024 and Provides Corporate Update - Yahoo Finance
Head-To-Head Review: Mosaic ImmunoEngineering (OTCMKTS:CPMV) & Outlook Therapeutics (NASDAQ:OTLK) - Defense World
Outlook Therapeutics® to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference - ForexTV.com
Outlook Therapeutics® to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference - GlobeNewswire
Outlook Therapeutics® to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference - Yahoo Finance
Why Is Caligan Partners Bullish on Outlook Therapeutics Inc (OTLK) Right Now? - Yahoo Finance
Outlook Therapeutics (OTLK) Set to Announce Quarterly Earnings on Wednesday - MarketBeat
Outlook Therapeutics (OTLK) Scheduled to Post Earnings on Wednesday - Defense World
Outlook Therapeutics® to Report Financial Results for Third - GlobeNewswire
Outlook Therapeutics® to Report Financial Results for Third Quarter Fiscal Year 2024 on August 14, 2024 and Host Quarterly Conference Call and Webcast - StockTitan
Virtu Financial LLC Trims Position in Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World
Trend Tracker for (OTLK) - Stock Traders Daily
American International Group Inc. Sells 74,302 Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World
Outlook Therapeutics, Inc. (NASDAQ:OTLK) Shares Sold by American International Group Inc. - MarketBeat
Outlook Therapeutics® to Present at the BTIG Virtual Biotechnology Conference 2024 - GlobeNewswire
Outlook Therapeutics® to Present at the BTIG Virtual Biotechnology Conference 2024 - StockTitan
BNP Paribas Financial Markets Has $54,000 Stock Holdings in Outlook Therapeutics, Inc. (NASDAQ:OTLK) - MarketBeat
BNP Paribas Financial Markets Has $54,000 Position in Outlook Therapeutics, Inc. (NASDAQ:OTLK) - MarketBeat
BNP Paribas Financial Markets Sells 81,876 Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World
1.26%
1.94%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):